An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions.
Binding kinetics
Degradation kinetics
Global sensitivity analysis
Mechanistic modelling
Model identifiability
PROTACs
Protein degradation
Journal
Journal of pharmacokinetics and pharmacodynamics
ISSN: 1573-8744
Titre abrégé: J Pharmacokinet Pharmacodyn
Pays: United States
ID NLM: 101096520
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
17
01
2023
accepted:
28
03
2023
medline:
29
8
2023
pubmed:
30
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
The value of an integrated mathematical modelling approach for protein degraders which combines the benefits of traditional turnover models and fully mechanistic models is presented. Firstly, we show how exact solutions of the mechanistic models of monovalent and bivalent degraders can provide insight on the role of each system parameter in driving the pharmacological response. We show how on/off binding rates and degradation rates are related to potency and maximal effect of monovalent degraders, and how such relationship can be used to suggest a compound optimization strategy. Even convoluted exact steady state solutions for bivalent degraders provide insight on the type of observations required to ensure the predictive capacity of a mechanistic approach. Specifically for PROTACs, the structure of the exact steady state solution suggests that the total remaining target at steady state, which is easily accessible experimentally, is insufficient to reconstruct the state of the whole system at equilibrium and observations on different species (such as binary/ternary complexes) are necessary. Secondly, global sensitivity analysis of fully mechanistic models for PROTACs suggests that both target and ligase baselines (actually, their ratio) are the major sources of variability in the response of non-cooperative systems, which speaks to the importance of characterizing their distribution in the target patient population. Finally, we propose a pragmatic modelling approach which incorporates the insights generated with fully mechanistic models into simpler turnover models to improve their predictive ability, hence enabling acceleration of drug discovery programs and increased probability of success in the clinic.
Identifiants
pubmed: 37120680
doi: 10.1007/s10928-023-09857-9
pii: 10.1007/s10928-023-09857-9
pmc: PMC10460745
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-349Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Drug Discov. 2022 Mar;21(3):181-200
pubmed: 35042991
Chem Soc Rev. 2022 May 10;51(9):3477-3486
pubmed: 35438107
Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):295-302
pubmed: 19331592
Nat Rev Drug Discov. 2016 Feb;15(2):87-95
pubmed: 26678621
Rev Med Chir Soc Med Nat Iasi. 2012 Jan-Mar;116(1):347-52
pubmed: 23077920
J Am Chem Soc. 2013 Apr 24;135(16):6092-9
pubmed: 23544844
Drug Discov Today Technol. 2015 Oct;17:9-15
pubmed: 26724331
AAPS J. 2016 Jan;18(1):64-91
pubmed: 26542613
Br J Pharmacol. 2016 Aug;173(15):2319-34
pubmed: 27129075
J Med Chem. 2015 Jun 25;58(12):4883-7
pubmed: 26039356
BMC Bioinformatics. 2009 Nov 09;10:371
pubmed: 19900289
PLoS One. 2012;7(5):e36321
pubmed: 22606254
Nat Rev Drug Discov. 2006 Sep;5(9):730-9
pubmed: 16888652
Cell. 2019 Aug 8;178(4):949-963.e18
pubmed: 31353221
ACS Bio Med Chem Au. 2022 Nov 15;3(1):74-86
pubmed: 37101604
Proteomics. 2017 Mar;17(6):
pubmed: 28127872
Sci Rep. 2016 Jul 25;6:29752
pubmed: 27452732
IET Syst Biol. 2009 Sep;3(5):329-41
pubmed: 21028924
J Biomol Screen. 2015 Jul;20(6):748-59
pubmed: 25851036
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8697-702
pubmed: 16735474
Syst Synth Biol. 2007 Apr;1(2):59-87
pubmed: 19003437
Elife. 2016 Jul 13;5:
pubmed: 27410477
IEEE/ACM Trans Comput Biol Bioinform. 2013 Jul-Aug;10(4):957-69
pubmed: 24334389
Br J Cancer. 2019 Jul;121(2):101-108
pubmed: 31231121
Cancer Cell. 2020 Apr 13;37(4):496-513
pubmed: 32289273
Drug Discov Today. 2013 Feb;18(3-4):116-27
pubmed: 22999913
Front Physiol. 2016 Dec 05;7:590
pubmed: 27994553
Anal Chem. 2008 Jul 15;80(14):5550-5
pubmed: 18543951
J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):149-163
pubmed: 33090299
Mol Endocrinol. 2008 Jul;22(7):1535-51
pubmed: 18388150
J Biol Chem. 2020 Nov 6;295(45):15280-15291
pubmed: 32859748
Pharmacol Ther. 2018 Apr;184:177-188
pubmed: 29024741
Mol Cell Proteomics. 2002 May;1(5):376-86
pubmed: 12118079
Mol Biosyst. 2013 Jun;9(6):1381-9
pubmed: 23478789
ACS Chem Biol. 2018 Feb 16;13(2):467-474
pubmed: 28892606
Drug Discov Today. 2002 Oct 15;7(20 Suppl):S192-6
pubmed: 12546905
Front Chem. 2021 Apr 20;9:672267
pubmed: 33959589